Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells
Qingbin Cui(St. John's University), Zhe‐Sheng Chen(New York College of Traditional Chinese Medicine), Ning Ji(Guiyang University), Suneet Shukla(National Cancer Institute), Dong‐Hua Yang(New York College of Traditional Chinese Medicine), Suresh V. Ambudkar(National Institutes of Health), Pranav Gupta(St. John's University), Liang Ren(Guangxi Medical University), Chao‐Yun Cai(St. John's University), Hailing Gao(Hefei University of Technology), Yuqi Yang(Minzu University of China)
Cited by 42
Related Papers
Microbiota in health and diseases
|Signal Transduction and Targeted Therapy|2022|2.9k
The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes
|medRxiv|2020|387
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|385
Exploring Phytochemicals for Combating Antibiotic Resistance in Microbial Pathogens
|Frontiers in Pharmacology|2021|271
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
|Drug Resistance Updates|2022|257